Purpose:

To evaluate the efficacy and safety of combination therapy with intravitreal ranibizumab followed by dexamethasone implant as compared to dexamethasone implant alone in treating macular edema (ME) due to retinal vein occlusions (RVO).

Methods:

Retrospective, comparative study. Results: 18 patients had intravitreal ranibizumab followed by dexamethasone implant within 6 weeks of injection (group 1), 19 patients had dexamethasone implant alone (group 2). Within 6 months, there were significantly more patients in group 1 who had visual acuity (VA) gain of more than 2 lines (44% vs 5%, P=0.008) compared with group 2. VA gain occurred faster and ME recurred later in group 1.

Conclusion:

Combination therapy provides additional benefit to dexamethasone implant alone in ME due to RVO.